Using the intraoperative hand held probe without lymphoscintigraphy or using only dye correlates with higher sensory morbidity following sentinel lymph node biopsy in breast cancer: A review of the literature by Kim, Suk Chul et al.
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
World Journal of Surgical Oncology
Open Access Research
Using the intraoperative hand held probe without 
lymphoscintigraphy or using only dye correlates with higher sensory 
morbidity following sentinel lymph node biopsy in breast cancer: A 
review of the literature
Suk Chul Kim1, Dong Wook Kim1, Renee M Moadel2, Chun K Kim1, 
Samprit Chatterjee3, Michail K Shafir4, Arlene Travis1, Josef Machac1 and 
Borys R Krynyckyi*1
Address: 1Department of Radiology, Division of Nuclear Medicine, The Mount Sinai School of Medicine, The Mount Sinai Hospital, New York, 
New York, USA, 2Department of Nuclear Medicine, Albert Einstein College of Medicine of Yeshiva University, and the Montefiore Medical Center, 
Bronx, New York, USA, 3Department of Health Policy, The Mount Sinai School of Medicine, The Mount Sinai Hospital, New York, New York, USA 
and 4Department of Surgery, The Mount Sinai School of Medicine, The Mount Sinai Hospital, New York, New York, USA
Email: Suk Chul Kim - sukchulkim@gmail.com; Dong Wook Kim - mdwook@empas.com; Renee M Moadel - rmoadel@montefiore.org; 
Chun K Kim - chun.kim@msnyuhealth.org; Samprit Chatterjee - samprit.chatterjee@msnyuhealth.org; 
Michail K Shafir - michail.shafir@msnyuhealth.org; Arlene Travis - arlene.travis@mssm.edu; Josef Machac - josef.machac@mssm.edu; 
Borys R Krynyckyi* - syrob@msn.com
* Corresponding author    
Abstract
Background: There are no studies that have directly investigated the incremental reduction in sensory morbidity that
lymphoscintigraphy images (LS) and triangulated body marking or other skin marking techniques provide during sentinel lymph
node biopsy (SLNB) compared to using only the probe without LS and skin marking or using only dye. However, an indirect
assessment of this potential for additional sensory morbidity reduction is possible by extracting morbidity data from studies
comparing the morbidity of SLNB to that of axillary lymph node dissection.
Methods: A literature search yielded 13 articles that had data on sensory morbidity at specific time points on pain, numbness
or paresthesia from SLNB that used radiotracer and probe or used only dye as a primary method of finding the sentinel node
(SN). Of these, 10 utilized LS, while 3 did not utilize LS. By matching the data in studies not employing LS to the studies that did,
comparisons regarding the percentage of patients experiencing pain, numbness/paresthesia after SLNB could be reasonably
attempted at a cutoff of 9 months.
Results: In the 7 studies reporting on pain after 9 months (> 9 months) that used LS (1347 patients), 13.8% of patients reported
these symptoms, while in the one study that did not use LS (143 patients), 28.7% of patients reported these symptoms at > 9
months (P < 0.0001). In the 6 studies reporting on numbness and/or paresthesia at > 9 months that used LS (601 patients), 12.5%
of patients reported these symptoms, while in the 3 studies that did not use LS (229 patients), 23.1% of patients reported these
symptoms at > 9 months (P = 0.0002). Similar trends were also noted for all these symptoms at ≤ 9 months.
Conclusion: Because of variations in techniques and time of assessing morbidity, direct comparisons between studies are
difficult. Nevertheless at a minimum, a clear trend is present: having the LS images and skin markings to assist during SLNB
appears to yield more favorable morbidity outcomes for the patients compared to performing SLNB with only the probe or
performing SLNB with dye alone. These results are extremely pertinent, as the main reason for performing SLNB itself in the
first place is to achieve reduced morbidity.
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Background
There is a trend towards minimally invasive surgery in all
aspects of breast cancer management. In keeping with this
trend is the increasing popularity of sentinel lymph node
biopsy (SLNB), which has been shown to result in lower
levels of morbidity in the staging of patients with breast
cancer as compared to conventional axillary lymph node
dissection (ALND) [1-20]. Therefore, it has essentially
become the standard of care [21]. Furthermore, SLNB
potentially provides even better staging than ALND, as
SLNB offers the added benefit of allowing for a more
extensive histological analysis of the SNs, by allowing for
additional sections through nodes, and by making it pos-
sible to use additional immunohistochemical staining
methods. These added maneuvers are not routinely per-
formed on nodes obtained from "classical" ALND, since
there are too many nodes available for examination from
ALND, and testing all of them is not feasible. [22,23].
The role that lymphoscintigraphy (LS) images play in
reducing morbidity during SLNB vs. using only the probe
without images or using only dye has not been formally
examined. Surgeons from ours and other institutions find
LS and triangulated body marking (TBM) or other skin
marking techniques essential during SLNB [22-26], while
others do not find the images or markings helpful [27-
29].
Theoretically, an accurate 3-dimentional representation of
the number and location of SNs in the body in the form
of LS images and TBM reference points or other skin mark-
ings, should expedite surgery by allowing a more targeted,
minimally invasive approach. This should limit the
amount of dissection, and therefore, the level of morbid-
ity. This is an important issue, as the main purpose for
performing SLNB is morbidity reduction.
Since no direct studies have investigated the additional
reduction in sensory morbidity that LS images and TBM
may provide during SLNB, an indirect assessment of this
potential was performed by extracting sensory morbidity
data on SLNB from studies comparing the morbidity of
SLNB to that of ALND [1-20] as described below.
Methods
The computerized bibliographic databases of PubMed
and Medline were searched. The key words used in the
search included breast, node, and morbidity. In addition,
an extensive manual search and cross-referencing from
review and original articles was performed. The global
inclusion criteria were prospective and retrospective stud-
ies that listed any sensory morbidity related to SLNB in
breast cancer patients.
Information on study design, lymphoscintigraphy tech-
niques, time of follow-up, and patients' characteristics
were collected from the searched articles. When informa-
tion was not present in the referenced text, personal com-
munications were initiated with the authors to obtain
additional information missing from the text; mainly to
establish the use or non-use of LS. Based on the informa-
tion from the articles and personal communications with
the authors, 20 articles were found that met these initial
criteria [1-20] (Table 1). Three comparisons were made,
based on decreasingly stringent levels of comparative
parameters described below.
Initial comparisons
For the initial set of comparisons, parameters of morbid-
ity assessment included; 1) pain in the arm or axilla, and
2) numbness on the operated side and/or paresthesias. A
subset of the group of 3 studies not using LS were com-
pared to a subset of the 17 studies that used LS. Studies
were matched as closely as possible based on the mean
time frames of morbidity assessment, to generate best
matched time frames of assessing morbidity.
Excluded studies and exclusion criteria for the initial 
comparisons
The study by Schrenk et al [1] was initially excluded,
because SLNB morbidity data were presented for a mixed
group of blue dye only and combined dye/radiotracer
procedures.
The study by Temple et al [5] was excluded, as a unique
morbidity scoring system was employed that could not be
adapted in any way for the comparisons. In addition,
prevalence data was reported, but the number of patients
experiencing symptoms could not be extracted.
One of the two studies by Haid et al [7] was excluded, as
no data on the timing of symptom assessment were pro-
vided. Symptoms tend to decrease over time, and the time
of assessment is needed for any meaningful comparisons.
The study of Ronka et al [16] presented morbidity data
which were strictly confined only to the breast, excluding
the axilla where SLNB is performed, and therefore was
excluded.
Two studies by Rietman et al [12,17], were initially
excluded in this constrained comparison because the use
of lymphoscintigraphy was unclear [12,17,30-32] and
portions of the data in the initial earlier study were in
error [12,31,33]. In addition, there are suggestions that a
dissection intensive blue dye technique was used as the
main method of finding the SN over a more targeted radi-
otracer/probe method, which appeared to only have a sec-
ondary role in finding the SN [12,17,30-32]. These twoWorld Journal of Surgical Oncology 2005, 3:64 http://www.wjso.com/content/3/1/64
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studies [12,17] were based on the exact same population
of patients but at different time points of morbidity
assessment. Yet, the later study [17] fails to acknowledge
the existence of the earlier study and its results [12].
Luini A et al [19] presented morbidity data on a mixed
group of ALND and SLNB patients where pure SLNB data
could not be extracted. The study was therefore excluded.
We also initially excluded additional studies
[2,4,10,14,15,18], because pain and numbness and/or
parasthesia morbidity parameters were not assessed at
comparable time points to the remaining studies.
For all remaining studies, the criteria for assessing mor-
bidity was chosen as such: either symptoms were present
(yes) or absent (no). In studies where a sliding scale of
intensity was the method of reporting morbidity symp-
toms, the percentage of patients fitting into a percent
adjusted yes or no group was used [6,20].
After the initial study selection process described above, 7
studies were included in the initial comparative analysis.
Among the 7 studies, 5 used LS [8,9,11,13,20] and 2 did
not use LS [3,6] (Table 2).
The 7 studies were grouped into the same morbidity cate-
gory when data was available. Depending on follow-up
periods and sensory morbidity assessment techniques, a
total of 5 time periods were established.
The resulting comparable time periods of morbidity
assessments for pain were ≤ 1 month, 6 months and 12 to
15.4 months. Likewise, numbness/parasthesia morbidity
assessments were at 6 months and 12 to 15.4 months
(Table 2).
The statistical analysis was performed using R 2.01 soft-
ware available in the public domain. Fisher's exact test was
used to analyze the nominal variables in the form of fre-
quency tables. A result was considered to be significant
only if the P-value was lower than 0.05. All p-values
reported are two-sided.
Secondary comparisons
The 20 studies were then reanalyzed with less stringent
time of morbidity assessment criteria. Two time periods
were created to include the greatest number of studies in
the analysis and resulted in the time periods of ≤ 9
months and > 9 months for pain and numbness/paresthe-
sia (Table 3). This allowed the 6 initially excluded studies
from table 2[2,4,10,14,15,18], to be integrated into table
3, resulting in a total of 13 studies included in the second-
ary comparative analysis. Among the expanded group of
13 studies, 10 used LS [2,4,8-11,13-15,20] and 3 did not
use LS [3,6,18] (Table 3). Statistical analysis for Table 3
again utilized Fisher's exact test.
Table 1: Studies with data on sensory morbidity and sentinel lymph node biopsy in breast cancer (ref 1-20).
Reference Year Journal Country Sample Size Design Lymphoscintigraphy Mean Length 
of Follow-up
Schrenk P et al.(1) 2000 Cancer Austria 35 Prospective Used 15.4 M
Roumen RM et al.(2) 2001 Br J Surg Netherlands 100 Prospective Used 24 M
Burak WE et al.(3) 2002 Am J Surg USA 48 Prospective Not Used 15.4 M
Haid A et al.(4) 2002 Breast Ca Res T Austria 57 Retrospective Used 18 M
Temple LK et al.(5) 2002 Ann Surg Oncol USA 171 Prospective Used 3 M, 6 M, 12 M
Swenson KK et al.(6) 2002 Ann Surg Oncol USA 169 Prospective Not Used 1 M, 6 M, 12 M
Haid A et al.(7) 2002 Eur J Surg Ocol Austria 66 Prospective Used Not specified
Leidenius M et al.(8) 2003 Am J Surg Finland 49 Prospective Used 2 W
Schijven MP et al.(9) 2003 Eur J Surg Oncol Netherlands 180 Retrospective Used 12 M
Blanchard DK et al.(10) 2003 Arch Surg USA 685 Prospective Used 2.4 Y
Veronesi U et al.(11) 2003 N Engl J Med Italy 100 Prospective Used 6 M, 24 M
Rietman JS et al.(12) 2003 Cancer Netherlands 66 Prospective Used* 6 W
Peintinger F et al.(13) 2003 Br J Cancer Austria 25 Prospective Used 1 W, 9–12 M
Baron RH et al.(14) 2004 Oncol Nurs Forum USA 197 Prospective Used 24 M
Armer J et al.(15) 2004 Lymphololgy USA 9 Retrospective Used 9 M
Ronka RH et al.(16) 2004 Acta Oncol Finland 57 Prospective Used 12.6 M
Rietman JS et al.(17) 2004 Ann Surg Oncol Netherlands 66 Prospective Used* 12 M
Langer S et al.(18) 2004 Am Surg USA 40 Retrospective Not Used 51 M
Luini A et al.(19) 2005 Breast Ca Res T Italy 244 Prospective Used 6–12 M
Ronka RH et al.(20) 2005 Breast Finland 43 Prospective Used 12 M
*Use/method of lymphoscintigraphy unclear, radiotracer used as backup method of finding sentinel node compared to primary dye based technique.World Journal of Surgical Oncology 2005, 3:64 http://www.wjso.com/content/3/1/64
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Tertiary comparisons
To further maximize the number of studies compared and
be as inclusive as possible, additional studies were inte-
grated into a tertiary analysis by relaxation of criteria.
These included the study by Schrenk et al [1], where the
heterogeneity of the data set as noted above was over-
looked, and the two articles by Rietman et al [12,17], by
discounting the issues related to them as noted above and
including them in the analysis (Table 4).
Issues with the remaining articles [5,7,16,19] continued
to be too significant to be reasonably included in the ter-
tiary comparison, as no meaningful data could be
extracted for the reasons already noted above. Statistical
analysis for Table 4 again employed Fisher's exact test.
Among the 20 articles, there were several with similar or
partly overlapping patient populations. Specifically the
articles of Leidenius M et al [8] and Ronka RH et al [20],
as well as Rietman JS et al [12,17] fit this pattern. How-
ever, for these articles the times of morbidity assessment
were different, so no overlapping of patient populations
occurred in any of the comparisons. In one group of arti-
cles, Temple et al [5] and Baron RH et al [14], the former
was not included in any of the comparisons for reasons
already mentioned above, so no overlapping patient
Table 2: Initial comparisons. Comparisons of studies at specific time points that met the constrained criteria detailed in the initial 
comparison (see text).
Morbidity Mean Length of F/U Lymphoscintigraphy (+) Lymphoscintigraphy (-) p-value
Mor (%) Total Pt (N) References Mor (%) Total Pt (N) References
Pain ≤ 1 m 31.08% 74 8,13 56.52% 161 6 0.0004
6 m 16.00% 100 11 37.50% 152 6 0.0002
12–15.4 m 11.71% 222 9,20 28.67% 143 6 < 0.0001
Numbness/Paresthesia 6 m 2.00% 100 11 30.26% 152 6 < 0.0001
12–15.4 m 4.50% 222 9,20 22.75% 189 3,6 < 0.0001
Table 3: Secondary comparisons. Comparisons of studies at two time periods that met the criteria detailed in the secondary 
comparison (see text).
Morbidity Mean Length of F/U Lymphoscintigraphy (+) Lymphoscintigraphy (-) p-value
Mor (%) Total Pt (N) References Mor (%) Total Pt (N) References
Pain Acute (≤ 9 m) 22.41% 174 8,11,13 47.28%* 161* 6 < 0.0001
Chronic (> 9 m) 13.81% 1347 2,4,9,10,11,14,20 28.67% 143 6 < 0.0001
Numbness/Paresthesia Acute (≤ 9 m) 5.50% 109 11,15 35.58%* 160* 6 < 0.0001
Chronic (> 9 m) 12.48% 601 4,9,11,13,14,20 23.14% 229 3,6,18 0.0002
* The average morbidity at 1 month and 6 months in article 6. Pain morbidity at 1 month and 6 months are 56.52% (91/161) and 37.50% (57/152), 
respectively. Numbness/paresthesia morbidity at 1 month and 6 months are 40.63% (65/160) and 30.26% (46/152), respectively.
Table 4: Tertiary comparisons. Comparisons of studies at two time periods that met the revised (relaxed more encompassing) criteria 
detailed in the tertiary comparison (see text).
Morbidity Mean Length of F/U Lymphoscintigraphy (+) Lymphoscintigraphy (-) p-value
Mor (%) Total Pt (N) References Mor (%) Total Pt (N) References
Pain Acutet (≤ 9 m) 22.41% 174 8,11,13 47.28%* 161* 6 < 0.0001
Chronic (> 9 m) 13.77% 1365 1,2,4,9,10,11,14,20 28.67% 143 6 < 0.0001
Numbness/Paresthesia Acute (≤ 9 m) 27.43% 175 11,12,15 35.58%* 160* 6 0.1254
Chronic (> 9 m) 12.56% 677 1,4,9,11,13,14,17,20 23.14% 229 3,6,18 0.0003
* The average morbidity at 1 month and 6 months in article 6. Pain morbidity at 1 month and 6 months are 56.52% (91/161) and 37.50% (57/152), 
respectively. Numbness/paresthesia morbidity at 1 month and 6 months are 40.63% (65/160) and 30.26% (46/152), respectively.
t This comparison remained unchanged from table 3.World Journal of Surgical Oncology 2005, 3:64 http://www.wjso.com/content/3/1/64
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population issues occurred when the latter was included
in the comparisons. For the studies of Roumen RM et al
[2] and Schijven MP et al [9], there potentially appeared to
have been very minimal overlap of patient populations.
The earlier prospective study [2] had data from 90 patients
from one hospital, while the later retrospective study [9]
had data on 180 patients from the same hospital as well
as another hospital, with the later study [9] data collected
mainly outside the timeframe of the earlier study [2]. Cor-
respondence with the author of the earlier study [2] sug-
gested no overlap with independent cohorts. Both studies
were therefore included in the analysis.
Results
For studies that met the constrained criteria, for all com-
parison periods, there was less pain and numbness/par-
esthesia morbidity reported for studies using LS than
those that did not, as shown in Table 2. The differences
were highly statistically significant (< 0.001). Similar
results were obtained in the secondary comparisons, in
which the time of morbidity assessment was segregated
into two time periods, allowing more studies to be
included in the analysis, as shown in Table 3. For the ter-
tiary comparisons in which inclusion criteria were relaxed
as described above to maximize the number of studies
included, all comparisons showed lower morbidity when
LS was used, but only 3 out of 4 were statistically signifi-
cant (see Table 4). The p-value for the numbness/par-
esthesia comparison at ≤ 9 months did not reach
statistical significance (0.1254). Globally, for the three
levels of comparison (Tables 2, 3, 4), all 12 unique
comparisons, using various inclusion/exclusion criteria,
showed less morbidity for the LS groups. In 11 out of the
12 unique comparisons, the p-values were highly
statistically significant (p-value range < 0.0001 to
0.0004). The results for numbness/paresthesia at > 9
months shown in Table 4 are especially pertinent, as this
reflects long term outcomes and includes the largest
number of patients, and the greatest number of LS and
non LS studies.
Discussion
The concept that using LS further reduces morbidity over
that of using the probe without LS or using dye alone is
intriguing to say the least. The analysis we performed sug-
gests that a strong trend exists for additional morbidity
reduction in the groups using LS.
The results from this analysis can also be conceptualized
from a purely theoretical standpoint; that is: mapping out
the location of the SNs in three dimensions prior to inci-
sion, knowing the true number of "hot" SNs (or lack of
nodes) and the relative intensity and time of appearance
to one another should facilitate a targeted surgical
approach. Surgeons can plan their approach with this
information and adjust their dissection based on the find-
ings of the probe with/without concurrent use of dye.
The results are also supported by the experience of sur-
geons who have access to high quality LS and skin mark-
ings and understand how to use the information. They are
of the opinion that both the corresponding images and
markings allow for a more directed dissection [23,26].
The studies reviewed in the analysis were not directly try-
ing to evaluate whether LS further reduces morbidity. Had
they been, it can be speculated that potentially even better
results could have been obtained with LS, especially as the
techniques of LS, TBM/skin marking, and SLNB continue
to evolve [22-26,34-41], with a renewed focus on accurate
anatomical delineation and minimally invasive surgery.
In addition, 9 studies that employed LS indicated that
they used variable forms of skin marking. Had all studies
that employed LS used an updated version of this tech-
nique of 3-dimensional SN reference, i.e. TBM, a further
morbidity reduction could have potentially been achieved
by directing an even more targeted surgical approach
[34,36,41].
The greatest limitation of our analysis is that there are
only a few studies that did not employ LS (n = 3). Most of
the comparisons in the tables were with only a single non
LS study [6]. Nevertheless, the results of nearly all compar-
isons are consistent with results from the specific compar-
isons that contained 3 non LS studies. The number of
studies employing LS was much greater, and provides sta-
ble estimates for the proportion having the morbidities of
pain and numbness/paresthesias. Because of variations in
techniques, time and method of assessing morbidity,
direct comparisons between studies are difficult and sub-
ject to confounding issues.
The number of nodes removed, use of radiotherapy after
SLNB, use of dye in addition to radiotracer, and the har-
vesting of level III SNs and/or non-axillary nodes could
potentially also influence the level of morbidity. These
factors were not scrutinized as the information was not
consistently available in the referenced articles. For exam-
ple, information on the biopsy of non-axillary nodes was
available only for one reference [8], where 16% (8/49) of
SN biopsied were non-axillary. While our study results
show an overwhelming advantage for using LS (+) over no
LS (-) (essentially a 50% reduction in sensory morbidity at
P < 0.0001–0.0003), we are very conservatively describing
the results as only a "strong trend" or correlation for the
reasons noted above.
Many clinicians dispute any advantages that LS and skin
markings may provide in serving the patient during SLNB
[27-29,42,43]. The reasons for this could be partlyWorld Journal of Surgical Oncology 2005, 3:64 http://www.wjso.com/content/3/1/64
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explained by the great variability in the quality of LS stud-
ies that are performed [23,27,28,34-37], and/or perhaps
by difficulties on the part of the surgeons in integrating
the information provided by LS and skin markings into
their surgical techniques during SLNB. Surgical tech-
niques need to be addressed in the pursuit of morbidity
reduction. Training tools for surgeons have been devel-
oped that have the potential for integrating the informa-
tion from LS and skin markings, with the goal of
performing minimally invasive surgery [38,40].
When the surgeons have a 3-dimensional concept and
image of the location of SNs prior to surgery, they are then
able to fine tune their surgical approach. An example of
this ability to fine tune surgical approach can be applied
to a hypothetical case of an upper outer quadrant breast
lesion. Initially, the surgeon may plan to attempt to reach
the SN via the tumor excision site in an attempt to reduce
morbidity. However, when provided with LS images and
skin markings the surgeon might realize that this is not
the optimal approach from a standpoint of morbidity
reduction, and would be able to plan an alternative
approach that further minimizes morbidity. It is conceiv-
able that more experienced, better informed surgeons are
more likely to utilize LS because of its benefits, and that
these surgeons perform a more delicate dissection result-
ing in less morbidity. However, the exact contribution of
LS vs. the skill level of the surgeons that directly contrib-
utes to this reduction in morbidity can not be independ-
ently deduced from the data in the articles.
Based on this analysis, the surgical evaluation of the sen-
tinel node in the axilla should utilize LS, TBM or other
skin marking techniques, and a probe guided dissection in
order to reduce sensory morbidity.
Conclusion
Though no randomized studies exist that directly ask this
question, our literature analysis suggests that lymphoscin-
tigraphy imaging is a very useful tool in further reducing
morbidity during sentinel lymph node biopsy.
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